Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹13,675 Cr
verified against source
Revenue YoY
10.5%
reported change
EBITDA
₹4,009 Cr
latest reported figure
Source
nse xbrl
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sun Pharma delivered a solid Q3 FY25 with consolidated sales of INR 13,437 crore, up 10.5% YoY, driven by strong India (13.8% growth) and emerging markets (10.1% growth). EBITDA margin expanded 120 bps YoY to 29.3%, aided by lower material costs and milestone income. Adjusted PAT grew 24.1% YoY to INR 3,220 crore. Specialty sales rose 24.8% to $370M, with balanced contribution from US and ex-US markets. India business gained 40 bps market share to 8.2%, led by volume and new launches. R&D spend was lower than guided at 6.3% of sales due to clinical trial delays; FY25 R&D guidance trimmed to <7%. Management remains focused on specialty pipeline, including Leqselvi (litigation oral arguments in April) and Antibe acquisition. Key risk: potential US tariff policy changes and FDA compliance issues at Halol facility could impact generics recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales.
- Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026.
- Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.
Risks flagged
- Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.
- Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.
- If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.
- Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones.
Key quotes
- We will remain opportunistic, but the focus on dermatology and ophthalmology will continue.
- The growth in specialty, whether looked at quarter-on-quarter, year-on-year, has come from both U.S. and ex-U.S. markets.
- We have invited the agency to inspect our Halol, but when to inspect is a decision that they take.
Research modules